CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1.
Xu J, Ji L, Liang Y, Wan Z, Zheng W, Song X, Gorshkov K, Sun Q, Lin H, Zheng X, Chen J, Jin RA, Liang X, Cai X. · 2020
Read CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. by Xu J, Ji L, Liang Y, Wan Z, Zheng W, Song X, Gorshkov K, Sun Q, Lin H, Zheng X, Chen J, Jin RA, Liang X, Cai X. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7762756.txt.
Introduction
Xu and co-authors identify a circular RNA that helps liver cancer resist a key drug. The drug is sorafenib, the first-line therapy for advanced liver cancer. Resistance often grows within months and caps its value. The RNA, called circRNA-SORE, runs high in resistant cancer cells.
Removing this RNA made sorafenib kill cells far better. The RNA binds a master cancer protein, YBX1, and shields it from destruction. Cancer cells also ship the RNA in exosomes, which spreads resistance to neighbor cells. In mouse models, silencing the RNA with injected siRNA beat resistance. The authors propose this axis as a drug target.
Catalog record
| CREATOR | Xu J, Ji L, Liang Y, Wan Z, Zheng W, Song X, Gorshkov K, Sun Q, Lin H, Zheng X, Chen J, Jin RA, Liang X, Cai X. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1 By Junjie Xu, Lin Ji, Yuelong Liang, Zhe Wan, Wei Zheng, Xiaomin Song, Kirill Gorshkov, Qiming Sun, Hui Lin, Xueyong Zheng, Jiang Chen, Ren-an Jin Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-020-00375-5 ABSTRACT Abstract Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma (HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the mechanisms underlying resistance have not been fully clarified. Here we report that a circular RNA, circRNA-SORE (a circular RNA upregulated in sorafenib-resistant HCC cells), plays a significant role in sorafenib resistance in HCC. We found that circRNA-SORE is upregulated in sorafenib-resistant HCC cells and depletion of circRNA-SORE substantially increases the cell-killing ability of sorafenib. Further studies revealed that circRNA-SORE binds the master oncogenic protein YBX1 in the cytoplasm, which prevents YBX1 nuclear interaction with the E3 ubiquitin ligase PRP19 and thus blocks PRP19-mediated YBX1 degradation. Moreover, our in vitro and in vivo results suggest that circRNA-SORE is transported by exosomes to spread sorafenib resistance among HCC cells. Using different HCC mouse models, we demonstrated that silencing circRNA-SORE by injection of siRNA could substantially overcome sorafenib resistance. Our study provides a proof-of-concept demonstration for a potential strategy to overcome sorafenib resistance in HCC patients by targeting circRNA-SORE or YBX1. Subject terms: Gastrointestinal cancer, Drug development INTRODUCTION Hepatocellular carcinoma (HCC) is the most common primary liver tumor with an increasing global incidence. In 2018, HCC was the sixth most frequently diagnosed cancer and the fourth leading cause of cancer-related death worldwide.1 Sorafenib is the first FDA-approved targeted therapy for advanced HCC. A previous study showed that sorafenib prolonged the median overall survival (OS) by 2.3−3 months in advanced HCC patients that did not qualify for liver transplantation or resection.2 However, many HCC patients respond poorly to sorafenib or develop resistance after months of treatment.3 Sorafenib resistance in HCC is usually observed within 6 months of treatment.4 Compelling evidence has suggested that the primary and acquired resistance of sorafenib in HCC involves multiple mechanisms, including autophagy, epithelial−mesenchymal transition, cancer stem cells, tumor microenvironment, and epigenetic regulation, and a number of signaling pathways are suggested to be involved, such as Wnt/β-catenin, TGFβ, Ras/MEK/ERK, PI3K/Akt, TNFα/NF-κB, and JAK/STAT pathways.4 However, the mechanisms of sorafenib resistance, particularly in vivo and in HCC patients, have not been well studied and remain poorly understood. Circular RNAs (circRNAs) are a class of endogenous noncoding RNAs (ncRNAs) that show complex tissue- and stage-specific expression within the eukaryotic transcriptome.5 Compared with linear ncRNAs, circRNAs are much more stable because of their closed-loop structure. Increasing evidence has indicated roles of circRNAs in various cancer-related processes, such as tumor formation, progression, relapse, and drug resistance. One of the best-known functions of circRNA is serving as miRNA sponges by directly binding mRNAs. For example, ciRS-7, the first extensively characterized circRNA, binds miR-7 and acts as a specific miR-7 inhibitor to regulate genes downstream of miR-7 in various cancers.6,7 Recent studies have demonstrated that circRNAs can also function by interacting with proteins. For example, circRNA-FOXO3 was shown to inhibit cell cycle progression by forming ternary complexes with p21 and CDK2.8 Exosomes are a class of extracellular vesicles that play vital roles in numerous physiological and pathological processes, such as the maintenance of normal physiology, regulation of immune responses, and stimulation of tumor progression.9,10 Tumor-derived exosomes have important and fundamental roles in tumor progression.11 Recent studies have shown that tumor-derived exosomes may function as transmitters of drug resistance in different malignancies, including HCC.12,13 Moreover, circRNAs are enriched in exosomes in some cancers and could thus be used as a class of exosome-based cancer biomarkers.14 However, whether and how exosome-transmitted circRNAs are involved in cancer, especially in HCC, remain largely unknown. In this work, we found that circRNA_104797, which we renamed as circRNA-SORE (a circular RNA upregulated in sorafenib-resistant HCC cells), is critical for maintenance and spread of sorafenib resistance in HCC. We found that circRNA-SORE is upregulated in sorafenib-resistant HCC cells and silencing circRNA-SORE substantially increases sorafenib-induced apoptosis in HCC cells. Mechanistic studies revealed that circRNA-SORE interacts with YBX1 in the cytoplasm, thus preventing PRP19-mediated YBX1 ubiquitination and degradation in the nucleus. Moreover, we found that circRNA-SORE is transmitted by exosomes, and silencing circRNA-SORE in different mouse models leads to a significant increase of sorafenib efficacy. RESULTS CircRNA-SORE is overexpressed in sorafenib-resistant HCC cells Increasing evidence has indicated the involvement of circRNAs in various cancer-related processes. To examine possible circRNAs involved in mediating sorafenib resistance in HCC, we first established three sorafenib-resistant HCC cell lines (HepG2-SR, LM3-SR, and SKhep1-SR) by culturing cells with escalating doses of sorafenib (1–7 μM for HepG2-SR cells and 1–6 μM for LM3-SR and SKhep1 cells) for 12 months. We then confirmed sorafenib resistance in these three cell lines using the Real-time Cell Analysis xCELLigence System. Our results showed that the three sorafenib-resistant cell lines were insensitive to sorafenib and exhibited a faster growth rate under sorafenib treatment compared with their parental cell lines (Fig. 1a). Next, we conducted an Arraystar Human CircRNA Array analysis on parental and HepG2-SR cells as they showed most distinguished difference between parental and resistant cells, and identified 14 significantly upregulated and 14 downregulated circRNAs (circRNAs with fold change > 2 and p values < 0.05) in HepG2-SR cells compared with parental control cells (Fig. 1b, c). Among the 14 upregulated circRNAs, circRNA_104797 had the most impact on sorafenib resistance in HCC cells. qPCR analysis confirmed that circRNA_104797 was consistently increased in all three sorafenib-resistant cell lines (Fig. 1d). Thus, we renamed circRNA_104797 as circRNA-SORE (a circular RNA upregulated in sorafenib-resistant HCC cells). [Figure: CircRNA-SORE is overexpressed in sorafenib-resistant HCC cells. a Three sorafenib-resistant HCC cell lines (HepG2-SR, LM3-SR, and SKhep1-SR) were established and confirmed by the Real-time Cell Analysis xCELLigence System (Roche Applied Sciences). Curves demonstrate the inhibitory effect of sorafenib on parental (P) and sorafenib-resistant (SR) cell lines. b Hierarchical clustering of 14 upregulated circRNAs and 14 downregulated circRNAs in HepG2-SR cells compared with parental HepG2 cells by Arraystar Human CircRNA Array analysis. CircRNAs with fold change >2 and p < 0.05 were selected as significantly different. c Scatter plots (left panel) and volcano plots (right panel) of the differentially expressed circRNAs. Red dots indicate differentially expressed circRNAs (p < 0.05 and fold change > 2). d CircRNA_104797 levels (normalized by GAPDH) in parental (P) and resistant (R) cell lines treated with the indicated concentrations of sorafenib (7 μM for HepG2, 6 μM for LM3 and SKhep1) for 72 h. e Diagram illustrating back-splicing of circRNA-SORE from the TLE4 host gene. f Time-course of the relative expression of circRNA-SORE and TLE4 in HepG2-SR cells treated with actinomycin D (10 µg/mL). g qPCR analysis of circRNA-SORE and GAPDH mRNA in HepG2-SR, LM3-SR and SKhep1-SR cells with or without RNase R treatment for 30 min at 37 °C. h Relative expression of circRNA-SORE in mRNA and non-mRNA samples in the indicated cell lines. Three independent experiments with three technical repetitions were performed. Data are expressed as mean ± SEM (error bars). Statistical analyses used Student’s t test. ***p < 0.001. NS not significant] To identify the origin of circRNA-SORE, we checked the UCSC Genome Browser and found that circRNA-SORE (also